Details of the deal
Merck KGaA said it will buy Silence Therapeutics for $20 per share, worth about $1.3 billion in total, paid entirely in cash. The price represents a 130% premium to Silence’s last closing share price.
Key facts:
- Deal value: about $1.3 billion, all cash.
- Price: $20 per share, a 130% premium to the last close.
- Field: siRNA medicines that silence faulty genes.
- Expected closing: first quarter of 2027.
Gene-silencing technology
Silence Therapeutics develops siRNA, or small interfering RNA, medicines that can “silence” disease-causing genes by stopping them from producing harmful proteins. The approach opens up treatment options for many diseases that conventional drugs struggle to address.














